Netherlands· NL-89179cb5095f
JERAYGO 12,5 mg filmomhulde tabletten
A aprocitentan product containing aprocitentan, registered in Netherlands by Idorsia Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Aprocitentan is registered in 10 of 19 countries.
Countries holding a registration under ATC C02KN01 (aprocitentan), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Aprocitentan · ATC C02KN01
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- APROCITENTAN
- Manufacturer
- Idorsia Pharmaceuticals Deutschland GmbH
- Country
- Netherlands (NL)
- ATC code
- C02KN01
- ATC class
- Aprocitentan
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1818
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aprocitentan in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJERAYGOIdorsia Pharmaceuticals Deutschland GmbH, Lörrach
- SwitzerlandJeraygo 12.5 mg, FilmtablettenIdorsia Pharmaceuticals Ltd
- United StatesTRYVIOIdorsia Pharmaceuticals Ltd
- IcelandJERAYGOIdorsia Pharmaceuticals Deutschland GmbH
- PolandJeraygoIdorsia Pharmaceuticals Deutschland GmbH
- SwedenJERAYGO 12,5 mg Filmdragerad tablettIdorsia Pharmaceuticals Deutschland GmbH
- IrelandJERAYGO 12.5 mg film-coated tabletsIdorsia Pharmaceuticals Deutschland GmbH
- FinlandJERAYGOIdorsia Pharmaceuticals Deutschland GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jeraygo
- Liechtenstein · Jeraygo
- Norway · Jeraygo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/55aeb1ae-13f4-4ce2-b071-3e87a28c6ae2 GET /v1/drugs/55aeb1ae-13f4-4ce2-b071-3e87a28c6ae2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/jeraygo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Aprocitentan",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131149",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROLOSE (E 463)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ZWART (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"SILICIUMDIOXIDE, GEHYDRATEERD (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)",
"TRIETHYLCITRAAT (E 1505)"
],
"substances": [
"APROCITENTAN"
],
"leaflet_url": null,
"authorised_at": "2024/06/27",
"procedure_number": "EMEA/H/C/006080",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1818",
"additional_monitoring": "Y"
}See everything about aprocitentan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.